EUCTR2014-003384-38-DK进行中（未招募）1 期
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONSE IN PATIENTS WITH ATOPIC DERMATITIS. - Liberty AD Solo - Continue
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 475
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A patient must meet the following criteria to be eligible for inclusion in the study:
- •1. Must have completed the treatment phase in 1 of the two 16-week initial treatment
- •studies (R668-AD-1334 or R668-AD-1416).
- •2. Must have achieved at least 1 of the following 2 treatment success criteria:
- •IGA = 0 or 1 (clear or almost clear) at week 16 OR EASI-75 (at least 75% reduction in EASI score from baseline to week 16)
- •3. Must be willing and able to comply with clinic visits and study-related procedures
- •4. Must provide signed informed consent
- •5. Must be able to understand and complete study-related questionnaires
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 428
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 47
排除标准
- •A patient who meets any of the following criteria will be excluded from the study:
- •1. Receipt of rescue medication for AD in the initial treatment study
- •2. Any conditions that require permanent discontinuation of study treatment in either initial
- •treatment study
- •3. Planned or anticipated major surgical procedure during the patient’s participation in this
- •4. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed
- •during this study
- •Birth control exclusion criterion # 5is listed in protocol section 4.2.2
研究者
相似试验
进行中（未招募）
1 期
A study to confirm the efficacy and safety of different dupilumab dose regimens in adults with atopic dermatitis (AD)Atopic dermatitisEUCTR2014-003384-38-ESRegeneron Pharmaceuticals, Inc.440
进行中（未招募）
1 期
A STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO AT LEAST ONE TNF INHIBITORPsoriatic arthritis (PsA)MedDRA version: 18.1Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2013-001368-46-PLPfizer Inc., 235 East 42nd Street, New York, NY 10017390
进行中（未招募）
1 期
A STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO AT LEAST ONE TNF INHIBITORPsoriatic arthritis (PsA)MedDRA version: 18.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2013-001368-46-BEPfizer Inc., 235 East 42nd Street, New York, NY 10017390
进行中（未招募）
1 期
A STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO AT LEAST ONE TNF INHIBITORPsoriatic arthritis (PsA)MedDRA version: 18.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2013-001368-46-DEPfizer Inc., 235 East 42nd Street, New York, NY 10017390
进行中（未招募）
1 期
A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS.EUCTR2011-003668-55-DEPfizer Inc., 235 East 42nd Street, New York, NY 10017400